Coronary/Structural Heart

Saranas® Announces Initial Enrollment of Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support

SAFE-MCS Will Examine the Impact of the Early Bird® Bleed Monitoring System on Reducing Bleeding Complications in Patients Undergoing High Risk PCI with Mechanical Circulatory Support HOUSTON–(BUSINESS WIRE)–Saranas, Inc., has announced initiation and first patient enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk […]

Olink participates in one of the largest proteomics studies enabling new treatment options for patients with heart failure

UPPSALA, Sweden, Dec. 02, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that its project with Boehringer Ingelheim, assessing the potential utility of protein biomarkers in the empagliflozin EMPEROR studies, recently entered the data analysis phase. Empagliflozin, approved in the US under the tradename JARDIANCE, […]

Sugar molecule flushes away cholesterol and reverses blocked arteries

Gold Coast, Queensland, Australia, Dec. 02, 2021 (GLOBE NEWSWIRE) — Cholrem (Australia) Pty Ltd have produced a product CAVADEX (Beta-Cyclodextrin) which reverses heart disease by removing cholesterol from damaged and narrowed arteries after only a few months, resulting in reduced arterial plaque. Atherosclerosis, also known as heart disease, is the […]

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

Results previously presented in a Late-Breaking Science Session at the American Heart Association’s 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and co-primary endpoint of clinical hemostasis Bentracimab had no drug-related serious adverse events MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a […]

Robocath successfully completes first robotic coronary angioplasty with R‑One in China

Rouen, France, November 30, 2021 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today announces the successful completion of the first coronary angioplasty in China assisted by its R-One™ robotic platform. The procedure took place at the 301 Hospital in Beijing on […]

Neovasc Reducer™ System Receives National Reimbursement in France

First therapy to receive newly established French reimbursement designation VANCOUVER and MINNEAPOLIS, Nov. 30, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) system has been granted Prise en Charge Transitoire (“PECT”) reimbursement in France by the national health authority, Haute Autorité de Santé (“HAS”). The decision […]

Canon Medical Introduces Super-Resolution Deep-Learning Reconstruction for Cardiac CT Scans

Aquilion ONE / PRISM Edition Now Offers Precise IQ Engine (PIQE) DLR* and SilverBeam Filter* OTAWARA, Japan–(BUSINESS WIRE)–Canon Medical is breaking ground once again with the introduction of Precise IQ Engine (PIQE) DLR and SilverBeam filter in the latest version of the Aquilion ONE / PRISM edition. PIQE, super-resolution deep-learning […]

Milestone: MemorialCare Orange Coast Medical Center Performs 100th TAVR Procedure

FOUNTAIN VALLEY, CA – MemorialCare Orange Coast Medical Center (OCMC) has announced that its Transcatheter Aortic Valve Replacement (TAVR) Program’s cardiac team recently performed their 100th TAVR procedure. Transcatheter aortic valve replacement (TAVR) is a minimally-invasive procedure that allows the aortic valve in your heart to be replaced with a […]

The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System

VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance supporting the implantation of the Neovasc Reducer™ (“Reducer”) in appropriate patients suffering from refractory […]

Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen

– Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested – Key secondary endpoints were met including statistically significant reductions in triglycerides and angiopoietin-like-3 (ANGPTL3) at all doses tested – Pfizer is continuing to review the findings […]